Response to Letter to the Editor From Taguchi: "Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS"

J Clin Endocrinol Metab. 2022 May 17;107(6):e2651-e2652. doi: 10.1210/clinem/dgac111.
No abstract available

Keywords: bisphosphonates; bone metastases; denosumab; osteonecrosis of the jaw; osteoporosis.

Publication types

  • Letter
  • Comment

MeSH terms

  • Bisphosphonate-Associated Osteonecrosis of the Jaw* / etiology
  • Bone Density Conservation Agents* / adverse effects
  • Humans
  • Osteonecrosis* / chemically induced


  • Bone Density Conservation Agents